| DB ID | MyCo_3149 |
| Title | Serum (1→3)-β-D-glucan and galactomannan levels in patients with cystic fibrosis: a retrospective cohort study |
| Year | 2018 |
| PMID | 29587700 |
| Fungal Diseases involved | Aspergillosis |
| Associated Medical Condition | Cystic fibrosis |
| Genus | Aspergillus |
| Species | fumigatus |
| Organism | Aspergillus fumigatus |
| Ethical Statement | The study protocol was approved by the ethics committee of the Medical Faculty of the Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Germany (applica-tion number 7-17B). The need for informed consent was waived. |
| Site of Infection | None |
| Opportunistic invasive | None |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | BDG |
| Biomarker Full Name | 1-3-beta-D-Glucan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Germany |
| Cohort | Here conducted a retrospective cohort study at the Uni- versity Hospital Erlangen, Germany, a 1400-bed tertiary care hospital. All patients with CF (children, adolescents and adults), who presented to the CF outpatient clinic between September 2015 and October 2016, were en- rolled. Patients with a history of lung transplantation were excluded. The local cystic fibrosis cohort consisted of 137 patients. |
| Cohort No. | 137 |
| Age Group | 4–51 |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Cystic fibrosis (CF) is the most frequent lethal autosomal recessive disorder in Caucasians. It is caused by mutations in the cystic fibrosis transmembrane conductance regula- tor (CFTR) gene leading to impaired ion transport across epithelial cells. The disease affects primarily the exocrine glands, resulting in pancreatic insufficiency and progres-sive pulmonary disease; the latter is the major cause of morbidity and mortality in CF patients. Within the lungs, highly viscous sputum facilitates the colonization and in-fection of the lower respiratory tract with various microor-ganisms. |
| Technique | ELISA |
| Analysis Method | FDA Approved-Fungitell assay |
| ELISA kits | ELISA Kit- Platelia Aspergillus; Bio‐Rad laboratories, Marnes‐la- Coquette, France |
| Assay Data | FDA- Fungitell®, Cape Cod International, Inc.; Falmounth, MA, USA |
| Validation Techniques used | FDA Approved-Fungitell assay, FDA Approved -Platelia Aspergillus Ag ELISA |
| Up Regulation Down Regulation | Increase |
| Sequence Data | None |
| External Link | None |
